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Background: Retinopathy is the leading cause of
blindness among patients with type 2 diabetes mellitus
(DM). Hyperhomocysteinemia is a recently recognized
risk factor for cardiovascular disease, independent of
established risk factors.
Objective: To study the association between the ho-
mocysteine level and retinopathy among subjects with
and without DM.
Methods: We studied an age-, sex-, and glucose toler-
ance–stratified random sample of a 50- to 75-year-old gen-
eral white population in the Hoorn Study (N=625). Reti-
nal vascular changes (retinopathy) were assessed using
ophthalmoscopy and/or fundus photography. Hyperho-
mocysteinemia was defined as a serum total homocys-
teine level greater than 16 µmol/L.
Results: The prevalence of retinopathy was 9.8% (28/
285) in subjects with normal glucose tolerance, 11.8%
(20/169) in those with impaired glucose tolerance, 9.4%
(10/106) in those with newly diagnosed type 2 DM, and
32.3% (21/65) in those with known type 2 DM. The preva-
lence of retinopathy was 10.3% (39/380) in subjects with-
out hypertension and 16.3% (40/245) in subjects with
hypertension; it was 12.0% (64/534) in subjects with a
serum total homocysteine level of 16 µmol/L or less and
16.5% (15/91) in those with a serum total homocyste-
ine level of more than 16 µmol/L. After stratification for
DM and adjustment for age, sex, glycosylated hemoglo-
bin, and hypertension, the odds ratio (95% confidence
interval) for the relation between retinopathy and hy-
perhomocysteinemia was 0.97 (95% confidence inter-
val, 0.42-2.82) in patients without DM and 3.44 (95%
confidence interval, 1.13-10.42) in patients with DM
(P=.08 for interaction).
Conclusion: The findings suggest that hyperhomocys-
teinemia may be a risk factor for retinopathy in patients
with type 2 DM, but probably not in patients without DM.
Arch Intern Med. 2000;160:2984-2990
D IABETIC retinopathy is theleading cause of blind-ness among patients withtype 2 diabetes mellitus(DM).1,2 About one third
of all cases of impaired visual function in
patients with type 2 DM is attributable to
retinopathy, theremainder tocataract, glau-
coma, macular degeneration, and other
causes. Blindness has been estimated to be
25timesmorecommoninpersonswithDM
than in those without DM.3 After 20 years
ofhavingDM,morethan60%ofthepatients
with type 2 DM have some degree of reti-
nopathy.2 The pathogenetic mechanisms
of diabetic retinopathy are incompletely
understood.
Diabetic retinopathy seems to be es-
sentially a retinal vascular disorder, prob-
ably beginning in the capillary bed. Epide-
miological studies have shown that the risk
and severity of diabetic retinopathy are
strongly related to the duration of DM, hy-
perglycemia, and hypertension, and also,
but less consistently, to hypercholesterol-
emia and smoking.2,4-9 Furthermore, there
is a close relation between the presence of
diabetic retinopathy and the risk of micro-
albuminuria. Patients with type 2 DM, com-
pared with those without diabetic retinopa-
thy, have about a 2-fold increased risk of
developing microalbuminuria.10,11 Con-
versely, patients with DM who have mi-
croalbuminuria or macroalbuminuria, com-
pared with those with normoalbuminuria,
have a higher prevalence and an increased
severity of diabetic retinopathy, as well as
an increased risk of developing this com-
plication.12-15 Together these findings sug-
gest that diabetic retinopathy and micro-
albuminuria have certain pathogenetic
mechanisms in common.
Hyperhomocysteinemia is a recently
recognized risk factor for cardiovascular
disease independent of major cardiovas-
cular risk factors.16-18 In addition, hyper-
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homocysteinemia seems to be a risk factor for microal-
buminuria independent of major determinants, ie, DM,
hypertension, protein intake, and renal function.19 It is
unknown whether hyperhomocysteinemia is also asso-
ciated with and, thus, a possible contributing cause of
retinopathy in the general population. We therefore in-
vestigated this issue in the 50- to 75-year-old general white
population of the Hoorn Study.20
RESULTS
Of 5 right and 8 left eyes, ophthalmoscopic findings were
missing. Inaddition to thephotographsof148subjects that
were lost, photographs of 3 right and 4 left eyes were miss-
ing. Moreover, because of poor quality, photographs of 18
rightand20lefteyeswereungradable forretinopathy.Thus,
ophthalmologic data of 625 subjects were available for fur-
theranalysis;76%(477of625subjects)werebasedonboth
ophthalmoscopic and fundus photographic findings.
With regard to the fundus photographs, the k (95%
CI) between the ophthalmologists was 0.87 (0.78-0.96)
for the right eyes (n=437) and 0.95 (0.89-1.00) for the
left eyes (n=428), indicating a good agreement; be-
tween ophthalmoscopic and fundus photographic find-
ings, the k was 0.39 (range, 0.22-0.56) for the right eyes
(n=450) and 0.39 (range, 0.21-0.58) for the left eyes
(n=443), indicating moderate agreement.
The baseline characteristics of the study popula-
tion are presented in Table 1. The standardized preva-
lence of any retinopathy was 10.7%. The prevalence was
9.8% (28/285) in subjects with normal glucose toler-
ance, 11.8% (20/169) in subjects with impaired glucose
tolerance, 9.4% (10/106) in subjects with newly diag-
nosed DM, and 32.3% (21/65) in subjects with known
SUBJECTS AND METHODS
STUDY POPULATION
The Hoorn Study, conducted from 1989 to 1992, is a cross-
sectional survey of glucose tolerance and other cardiovascu-
lar risk factors in a 50- to 75-year-old general white popula-
tion.21 A random sample of all men and women aged 50 to 75
years was drawn from the municipal population registry of-
ficeofHoorn, theNetherlands;2484subjectsparticipated(re-
sponse rate, 71%). All subjects, except previously diagnosed
diabeticsubjectswithDMwhoweretreatedwithoralglucose-
loweringagentsor insulin,underwenta75-goral glucose tol-
erance test and were classified according to the World Health
Organization criteria.22 A second oral glucose tolerance test
(participation rate, 93%) was performed, for reasons of effi-
ciency, inarandomsubsample(n=1122), stratifiedby2-hour
glucose values of the first test, age, and sex. Finally, from this
subsampleanotherage-, sex-,andglucose tolerance–stratified
random sample (n=708) was drawn. The presence of retinal
vasculopathy(asdefinedbelow)was investigated(n=625; re-
sponse rate, 88%) by 2 experienced ophthalmologists. The
examinationincludedbothophthalmoscopyandfunduspho-
tography(detailedbelow).Glucosetolerancewasdividedinto
4 categories on the basis of the mean of the 2 oral glucose tol-
erance test results: subjects with normal glucose tolerance
(n=285), subjectswith impairedglucose tolerance (n=169),
subjectswithnewlydiagnosedDM(n=106),andsubjectswith
known DM(n=65). The Hoorn Study was approved by the
Ethical Review Committee of the University Hospital Vrije
Universiteit,Amsterdam, theNetherlands. Informedconsent
was obtained from all participants.
OPHTHALMOLOGIC INVESTIGATION
Retinopathy was assessed by ophthalmoscopy and/or fun-
dus photography. In each participant, both eyes were di-
lated with 0.5% tropicamide and 5% phenylephrine hy-
drochloride eye drops. After an average period of 15 minutes,
indirect and direct ophthalmoscopy (N=625) was carried
out by 1 of 2 ophthalmologists, and findings regarding the
retinal status were reported on standard forms. There-
after, two 45° standard field, 35-mm black-and-white
fundus photographs (Kodak Tri-X 400 ASA; Eastman
Kodak, Rochester, NY; Kowa Pro 1 fundus camera; Kowa
Optical Industry, Tokyo, Japan) were taken of each eye.
Photographs were taken with a green filter (to improve the
contrast), centered on the macular area and the optic disc.
Fundus photographs of 148 subjects were inadvertently lost.
(The fundus photographs were randomly lost with regard
to age, sex, hypertension, glucose tolerance category, and
serum total homocysteine [tHcy] level of the subjects [data
not shown].) Thus, for the present analysis fundus pho-
tographs of 477 subjects were available.
Bothophthalmoscopicandfundusphotographicfindings
were graded according to the modified Airlie House classifi-
cation.23,24Thefundusphotographswereindependentlygraded
by 2 ophthalmologists. The independent judgment of a third
ophthalmologist was taken to be decisive in case of disagree-
ment about the grading of retinopathy on the fundus photo-
graph. For the present analysis “the worst eye” of each sub-
jectaccordingtoophthalmoscopyor fundusphotographywas
used.24 Any retinopathy (yes/no) was defined as the presence
of1ormorehemorrhages,microaneurysms, softorhardexu-
dates, neovascularization, and/or laser coagulation scars in 1
or both eyes. Diabetic retinopathy was defined as presence of
1 or more microaneurysms and/or laser coagulation scars in
1 or both eyes (there were no subjects with neovasculariza-
tion), regardless of other abnormalities.
MEASUREMENT OF SERUM tHcy LEVEL
Fastingbloodsampleswerecentrifugedwithin1hour follow-
ingcollection.Serumsampleswerestoredat−20°C for6years.
cThereisgoodevidencethatserumtHcylevelsinfrozensamples
are stable for 10 years or longer.25 The serum tHcy (free plus
protein-bound)levelwasmeasuredusingtri-n-butylphosphine
as the reducing agent and ammonium 7-fluorobenzo-2-oxa-
1,3-diazole-4-sulfonateasthethiol-specificfluorochromophore,
followed by high-performance liquid chromatography with
fluorescence detection.26 The intra-assay and interassay co-
efficients are 2.1% and 5.1%, respectively.
OTHER MEASUREMENTS
Subjects were classified as either a current cigarette smoker
or nonsmoker. The body mass index was calculated as weight
Continued on next page
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DM; it was 10.3% (39/380) in subjects without hyper-
tension and 16.3% (40/245) in those with hyperten-
sion; it was 12.0% (64/534) in subjects with serum tHcy
levels of 16 µmol/L or less and 16.5% (15/91) in those
with serum tHcy levels higher than 16 µmol/L. The preva-
lence of diabetic retinopathy was 4.6% (13/285) in sub-
jects with normal glucose tolerance, 5.9% (10/169) in sub-
jects with impaired glucose tolerance, 4.7% (5/106) in
subjects with newly diagnosed DM, and 23.1% (15/65)
in patients with known DM. Figure 1 shows the preva-
lence of any retinopathy according to absence or pres-
ence of hyperhomocysteinemia (.16 µmol/L) in pa-
tients with and without DM. We chose this cutoff value
since risk of retinopathy increased markedly above this
value among subjects with DM (Table 2).
The median serum tHcy level was 12.2 µmol/L (in-
terquartile range, 10.0-15.3) in men and 10.7 µmol/L (in-
terquartile range, 9.0-13.3) in women. Serum tHcy levels
correlated with age (r=0.17; P,.001). After adjustment for
age and sex, the serum tHcy level correlated with the se-
rum creatinine level (r=0.4; P,.001), inversely with cre-
atinine clearance (r=−0.3; P,.001), but there was no sub-
stantial correlation between the serum tHcy levels and the
following variables: systolic BP (r=0.06; P=.1), diastolic
BP (r=−0.03; P=.5), body mass index (r=−0.02; P=.7),
fasting glucose level (r=−0.07; P=.07), fasting insulin
level (r = 0.05; P = .2), HbA1c level (r = −0.02; P = .6),
serum total cholesterol level (r=0.04; P=.3), or dura-
tion of DM in subjects with known DM (r = −0.03;
P=0.8).
After adjustment for age and sex, the OR (95% CI)
for any retinopathy was 1.37 (1.18-1.59) per percentage
of increment of HbA1c level, 1.76 (1.07-2.90) for DM (yes/
no), 1.57 (0.97-2.55) for hypertension (yes/no), 1.46
(in kilograms) divided by height (in meters), squared.
Blood pressure (BP) was measured, in total, as the mean
of 4 measurements, performed on 2 different occasions,
with a random 0 sphygmomanometer under standardized
conditions. Hypertension was defined as a BP of 160
mm Hg or more systolic and/or 95 mm Hg or more dias-
tolic and/or the current use of antihypertensive medica-
tion. Fasting and 2-hour postload venous plasma glucose
levels were measured with a glucose dehydrogenase
method (Merck, Darmstadt, Germany) and the glyco-
sylated hemoglobulin (HbA1c) level by ion-exchange,
high-performance liquid chromatography, using a DM
monitoring system (Modular Diabetes Monitoring Sys-
tem; Bio-Rad, Veenendaal, the Netherlands). The fasting
serum total cholesterol level was measured by enzymatic
techniques (Boehringer-Mannheim, Mannheim, Germany).
Hypercholesterolemia was defined as a total cholesterol
level of 6.5 mmol/L or higher ($251 mg/dL) and/or
the current use of cholesterol-lowering medication. The
serum creatinine level was measured by the modified
Jaffe´ method. Estimation of the serum creatinine clear-
ance was done according to the formula described by
Cockcroft and Gault.27 Immunospecific insulin was mea-
sured in serum by a double-antibody radioimmunoassay
(lot SP21; Linco Research, St Louis, Mo). The interassay
coefficient of variation was 6%. The lower limit of sensi-
tivity was 12 pmol/L. Ophthalmologic investigations and
laboratory measurements were carried out in a masked
fashion for glucose tolerance status and other clinical
data.
STATISTICAL ANALYSIS
Variables are presented as mean(SD), number (percentage
of the total), or, in case of skewed distribution, median
and interquartile range. For age, sex, and glucose tolerance
category, standardized prevalence of any retinopathy and
hyperhomocysteinemia was calculated, as described previ-
ously in detail.18 Briefly, the frequency was determined in
24 strata (age, 3; sex, 2; and glucose tolerance, 4) of the
subsample. To assess the standardized prevalence in
the original population-based sample (standard, N=2484),
the prevalence was calculated from the magnitude of each
age, sex, and glucose tolerance category stratum. k Coeffi-
cients were calculated to assess agreement with regard to
the presence of retinopathy on fundus photographs
between 2 ophthalmologists, and of the presence of reti-
nopathy between fundus photographic and ophthalmo-
scopic examinations. Differences between subjects with
and without any retinopathy were tested using the t test
or Wilcoxon rank sum test for continuous variables and
Pearson x2 test for frequency measures. Associations of
risk factors for retinopathy with serum tHcy level (loga-
rithmically transformed) were studied by calculation of the
Pearson product-moment correlation coefficients.
We performed logistic regression analyses to study the
relation between the serum tHcy level and the presence of
any retinopathy. The number of cases in the separate classes
of retinopathy was insufficient to allow a more detailed
analysis. We chose 2 different approaches to investigate the
nature of the relation between the serum tHcy level and
retinopathy, because it is unclear whether this relation, if
any, is linear or has a certain threshold. We calculated odds
ratios (ORs) and 95% confidence intervals (CIs) both for
the serum tHcy level as a categorical (to allow for a non-
linear dose-response relation and to reduce the influence
of outliers) and as a continuous variable, the latter ex-
pressed per 5-µmol/L (about 1 SD) increment of serum tHcy
level (restricted to the range from the minimum tHcy value
to 35 µmol/L). For analysis with the serum tHcy level as a
categorical variable, we calculated ORs for the tHcy value
divided in 2 (.16 µmol/L vs #16 µmol/L) and in 3 cat-
egories (#9.0 µmol/L, 9.1-16.0 µmol/L, and .16.0 µmol/L).
To test for trend, the 3 categories were entered in the model
as an ordinal variable. We used multiple logistic regres-
sion analysis to control for potential confounders, ie, age,
sex, glucose tolerance category, known duration of DM of
more than 10 years (in the present study a duration effect
was seen after 10 years, which is in agreement with other
studies2,5,28), HbA1c level, and hypertension. To exclude the
possibility of residual confounding as thoroughly as pos-
sible, we also tested models that, in addition, included se-
rum creatinine level, creatinine clearance, hypercholester-
olemia, current smoking, body mass index, and/or fasting
insulin level. Possible interaction between the tHcy level
and DM for risk of retinopathy was assessed in a stratified
analysis and with an interaction term. All analyses were per-
formed using SPSS for Windows 95 version 7.5.2 (SPSS,
Chicago, Ill). A 95% CI not including 1.0 was considered
to indicate statistical significance.
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(0.89-2.39) for hypercholesterolemia (yes/no), 1.09 (0.64-
1.86) for current smoking (yes/no), and (among sub-
jects with known DM) 7.31 (2.69-19.85) for a DM
duration of more than 10 years.
After stratification by DM (yes/no) and adjustment
for age, sex, HbA1c level, and hypertension, we observed
a substantial difference between the 2 strata with regard
to relative risk of retinopathy. The OR of retinopathy as-
sociated with hyperhomocysteinemia (.16 µmol/L) was
0.97 (95% CI, 0.42-2.82) in subjects without DM and 3.44
(95% CI, 1.13-10.42) in subjects with DM (P=.08 for
interaction); after additional adjustment for serum cre-
atinine clearance it was 1.01 (95% CI, 0.44-2.33) in sub-
jects without DM and 3.33 (95% CI, 0.99-11.19) in sub-
jects with DM, respectively. The results per category
increment of serum tHcy level are shown in Table 2 and
Figure 2 (P=.03 for interaction). This indicates that hy-
perhomocysteinemia is associated with retinopathy in sub-
jects with DM but not in subjects without DM. After ad-
justment for age, sex, HbA1c level, and hypertension, the
OR per 5-µmol/L increment of serum tHcy level was 0.89
(95% CI, 0.60-1.34) in subjects without DM and 1.50
(95% CI, 0.93-2.41) in subjects with DM. Additional ad-
justment for serum creatinine level, serum creatinine clear-
ance, hypercholesterolemia, current smoking, body mass
index, and/or fasting insulin level did not markedly change
the results (data not shown).
To reduce the effect of possible misclassification, we
repeated the analysis after classifying subjects with only
hemorrhages in one or both eyes as having no retinopathy
in an additional analysis. After adjustment for age, sex, and
HbA1c level, the OR for hyperhomocysteinemia was 1.11
(95% CI, 0.46-2.68) in subjects without DM and 5.28 (95%
CI, 1.67-16.67) in subjects with DM, and per 5-µmol/L in-
crement of serum tHcy level it was 0.96 (95% CI, 0.62-
1.48) and 1.64 (95% CI, 1.00-2.71), respectively. If dia-
betic retinopathy (see “Subjects and Methods” section) was
taken as the dependent variable, the OR for hyperhomo-
cysteinemia was 1.11 (95% CI, 0.36-3.41) in subjects with-
out DM and 4.45 (95% CI, 1.21-16.37) in subjects with DM,
and per 5- µmol/L increment of serum tHcy level it was 0.96
(95% CI, 0.55-1.66) and 1.45 (95% CI, 0.84-2.53), respec-
tively. Additional adjustment of the previous analyses for
hypertensionorBPrevealedsimilar results (datanot shown).
Among subjects with DM, after stratification for hyperten-
sion and adjustment for age and sex, the OR for hyperho-
mocysteinemia was 6.00 (95% CI, 0.37-96.80) among sub-
jects with normotension and 4.11 (95% CI, 0.95-17.79)
among subjects with hypertension. These ORs did not dif-
fer significantly from each other, which suggests that the
association between hyperhomocysteinemia and retinopa-
thy is independent of the presence of hypertension.
COMMENT
This population-based study indicates that hyperhomo-
cysteinemia is associated with retinopathy in subjects with
type 2 DM, independent of known determinants, ie, DM
duration, glycemic level, and hypertension. We found a
dose-response relation between the serum tHcy level and
retinopathy among subjects with type 2 DM (Table 2).
For each 5-µmol/L (about 1 SD) increment in serum tHcy
level, the risk of retinopathy rose by about 50% (95% CI,
−7 to 141) in the subjects with DM. Hyperhomocystein-
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Figure 1. Prevalence of retinopathy according to the absence or presence of
hyperhomocysteinemia (.16 µmol/L) in subjects with and without diabetes
mellitus (DM). Error bars represent the upper half of the 95% confidence
intervals.
Table 1. Characteristics of the Subjects*
Subject With
No Diabetic
Retinopathy
(n = 546)
Subjects With
Diabetic
Retinopathy
(n = 79) P †
Men, % 49.1 41.8 .3
Age, y 64.1 (7.3) 65.7 (6.7) .06
Body mass index, kg/m2 27.1 (3.9) 28.0 (4.5) .07
Current smoker, % 28.7 28.2 .9
Blood pressure, mm Hg
Systolic 138 (19) 147 (22) .001
Diastolic 82 (10) 85 (11) .04
Hypertension, % 37.5 50.6 .03
Glucose tolerance, %
Normal 47.1 35.4 . . .
Impaired 27.3 25.3 . . .
Newly diagnosed diabetes
mellitus, %
17.6 12.7 . . .
Known diabetes mellitus, % 8.1 26.6 ,.001‡
Duration of diabetes
mellitus, y§
5.9 (2.0-9.5) 9.4 (4.3-16.2) .02
Fasting glucose level,
mmol/L
6.5 (2.3) 7.8 (3.6) .002
Glycosylated hemoglobin,
% hemoglobin
5.8 (1.2) 6.6 (1.8) ,.001
Fasting insulin level, pmol/L 83 (62-116) 93 (72-143) .01
Total serum cholesterol
level, mmol/L
6.6 (1.2) 6.8 (1.2) .08
Hypercholesterolemia, % 53.5 63.3 .1
Total serum homocysteine
level, µmol/L
11.5 (9.3-14.1) 11.1 (9.4-14.0) .99
Serum creatinine level,
µmol/L
91 (17) 94 (30) .5
Serum creatinine clearance,
mL/min\
75 (17) 74 (19) .6
*Data are presented as mean (SD), percentage of the total or median
(interquartile range). Ellipsis indicates not applicable.
†Tested with t test or Wilcoxon rank sum test for continuous variables and
Pearson x2 test for frequencies.
‡x2 Test for trend.
§Diabetes duration since diagnosis of those subjects with known diabetes
mellitus.
\Estimated creatinine clearance.
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emia, defined as a serum tHcy level of 16 µmol/L or higher,
was also related to retinopathy among subjects with type
2 DM (OR, 3.4 [95% CI, 1.1-10.6]). The results of the
present study are in line with 2 studies that reported a
higher serum tHcy level in subjects with type 1 and type
2 DM who have diabetic retinopathy than in those with-
out DM.29,30 However, these studies did not investigate
the strength of the association between serum tHcy level
and retinopathy, nor has additional adjustment for im-
portant risk factors for retinopathy been performed. An-
other study showed an association between the pres-
ence of diabetic retinopathy and C677T polymorphism
of the methylenetetrahydrofolate reductase among pa-
tients with type 2 DM.31 This mutation in the methy-
lenetetrahydrofolate reductase gene was found in 5% to
15% of the general population. Persons who are homo-
zygous for this mutation appear to have impaired en-
zyme activity, leading to an exaggerated hyperhomocys-
teinemic response to a low intake of folic acid. In contrast,
Agardh et al,32 Araki et al,33 and Smulders et al34 found no
association between hyperhomocysteinemia and diabetic
retinopathy in types 1 and 2 DM, respectively. However,
none of these studies adjusted for the known determi-
nants of retinal vasculopathy and one32 was rather small.
Diabetic retinopathy involves both morphologic and
functional changes of the retinal capillaries.35,36 Hyper-
homocysteinemia may induce endothelial dysfunction and
injury followed by platelet activation and thrombus for-
mation, possibly by increasing oxidative stress.37 There-
fore, it is conceivable that hyperhomocysteinemia is caus-
ally related to retinal vasculopathy through changes of
the retinal vasculature and formation of microthrombi.
Since oxidative stress is thought to be increased in type
2 DM,38 this may make them more susceptible to hyper-
homocysteinemia-induced oxidative damage.
We can think of 3 sources of disease misclassifica-
tion that may have resulted in bias of the relation be-
tween hyperhomocysteinemia and retinopathy. Of 24%
of all subjects, the fundus photographs were missing, and,
therefore, in these subjects the diagnosis of retinopathy
was solely dependent on the ophthalmoscopic examina-
tion findings. There is evidence that the sensitivity to de-
tect retinopathy by ophthalmoscopy, even in the hands
of an experienced ophthalmoscopist, is lower than that
of fundus photography using color or black-and-white
transparencies.24,39-42 In addition, the method of detect-
ing any retinopathy with 2 stereoscopic standard fields
compared with 7 is slightly less sensitive (sensitivity about
0.85).42 Finally, a number of early small lesions may be
missed on 45° fundus photographs compared with pho-
tographs taken with a smaller angle. All 3 limitations of
the present study may have introduced false-negative dis-
ease misclassification, which was, in all likelihood, non-
differential for the serum tHcy level. This would tend to
underestimate the strength of the reported relation be-
tween hyperhomocysteinemia and retinopathy.43
In an additional analysis we showed, independent of
hypertension, a positive association between hyperhomo-
cysteinemia and diabetic retinopathy, with the presence of
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Figure 2. Odds ratio for retinopathy among subjects with and without diabetes
mellitus (DM), according to the serum total homocysteine level adjusted for
age, sex, glycosylated hemoglobin level, creatine clearance, and hypertension.
The reference category was serum total cholesterol values 9 to 16 µmol/L
(.348 to .619 mg/dL). The error bars represent the upper or lower half of the
95% confidence intervals. Asterisk indicates P,.05 for trend.
Table 2. Odds Ratios (95% Confidence Intervals) for Diabetic Retinopathy
Total Homocysteine
Level, µmol/L
Prevalence of Diabetic
Retinopathy, %*
Adjusted for
Age and Sex
Adjusted for Age,
Sex, HbA1c† Level,
and Hypertension
Adjusted for Age,
Sex, HbA1c, Hypertension,
and Serum Creatinine
Clearance
Adjusted for Age, Sex,
HbA1c Level, Hypertension,
and Diabetes Duration
.10 y
Subjects With Diabetes Mellitus
#9.0 10.0 (4/40) 0.53 (0.16-1.71) 0.56 (0.17-1.85) 0.56 (0.17-1.87) 0.54 (0.15-1.90)
9.1-16.0‡ 18.0 (20/111) 1.00 1.00 1.00 1.00
.16.0 35.0 (7/20) 2.68 (0.92-7.80) 3.05 (0.99-9.42) 3.09 (0.92-10.38) 3.00 (0.95-9.51)
Per category increment 2.28 (1.09-4.79) 2.38 (1.10-5.17) 2.37 (1.02-5.53) 2.41 (1.09-5.31)
P for trend .03 .03 .046 .03
Subjects Without Diabetes Mellitus
#9.0 12.1 (11/91) 1.38 (0.64-2.98) 1.52 (0.69-3.34) 1.47 (0.66-3.25)
9.1-16.0‡ 9.9 (29/292) 1.00 1.00 1.00
.16.0 11.3 (8/71) 1.19 (0.52-2.74) 1.05 (0.45-2.46) 1.08 (0.46-2.54)
Per category increment 0.91 (0.54-1.55) 0.82 (0.47-1.40) 0.85 (0.49-1.47)
P for trend .7 .5 .6
*For parenthetic values, the numerator indicates the number of subjects; denominator, the total number in the subpopulation.
†HbA1c indicates glysosylated hemoglobin.
‡Indicates reference category.
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microaneurysms as the defining characteristic. Although
microaneurysms are also related to certain other diseases
(eg, collagen vascular diseases or human immunodefi-
ciency virus retinopathy), these diseases are rare com-
pared with DM. Therefore, it is likely that our definition
of diabetic retinopathy is somewhat more specific for DM-
related retinal abnormalities than our definition for “any”
retinopathy. As the results of the analyses with any and with
diabetic retinopathy are quite similar, we believe that our
conclusions are unaffected by this issue.
The Beaver Dam Eye Study44 is a population-based
study among individuals without DM, aged 43 through
84 years, that reported a prevalence of retinopathy of 7.8%
as assessed by means of 2 standard photographic fields.
The Rotterdam Study,7 a population-based study of the
elderly persons (aged $55 years), reported a prevalence
of retinopathy of 4.8%, as detected by grading 1 stan-
dard photographic field, which is lower than the 10.7%
we found. The difference in reported prevalences may
partly be explained by less sensitive methods used to de-
tect retinopathy in the Rotterdam Study. In the present
study both ophthalmoscopic and photographic findings
were used to asses the presence of retinopathy. The poor
agreement we found between retinal photography and
ophthalmoscopy is comparable with other studies.45,46
We evaluated a possible dose-response relation be-
tween the serum tHcy level and retinopathy, because it
is unknown whether this relation is graded or has a cer-
tain threshold. The limited number of subjects with reti-
nopathy, however, did not allow for a precise assess-
ment of the presence of a possible threshold, which may
be at 16 µmol/L among subjects with type 2 DM, but this
result clearly needs to be confirmed in other studies. The
boundaries of the serum tHcy level categories were quite
broad and chosen post hoc. Another limitation is that,
owing to the limited number of subjects with retinopa-
thy, we could not explore the association between the
serum tHcy level and the separate degrees of diabetic reti-
nopathy. Since we did not assess B vitamins and the pres-
ent study is cross sectional, we cannot rule out the pos-
sibility that low vitamin B levels may cause diabetic
retinopathy or that diabetic retinopathy per se can raise
serum tHcy levels, although the latter appears biologi-
cally implausible.
CONCLUSIONS
Hyperhomocysteinemia is associated with retinopathy
among subjects with type 2 DM, but probably not in sub-
jects without DM. If the finding of the present study can
be confirmed in a prospective study, this may have im-
plications for the clinical management of subjects with
type 2 DM since the serum tHcy level can be lowered sub-
stantially with folic acid supplementation.47
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